Atossa Therapeutics, Inc.'s SEC filings document a clinical-stage biopharmaceutical issuer focused on (Z)-endoxifen development in oncology and rare disease settings. Its reports include financial-result 8-Ks, corporate updates, Regulation FD communications, and disclosures tied to research and development spending for its lead product candidate.
The filing record also covers governance and capital-structure matters, including annual meeting votes, director elections, auditor ratification, executive-compensation votes, charter-authority proposals, Form S-3 and at-the-market offering disclosures, Nasdaq listing compliance, and material events involving Endoxifen-related intellectual property proceedings and settlement agreements.
Atossa Therapeutics, Inc. declared a dividend of one stapled contingent value right (CVR) per common share outstanding at the close of business on October 19, 2026. Shares issued after that date and before detachment or expiration will also carry one CVR.
Holders are entitled collectively to 25% of net proceeds from the sale or deemed monetization of the first qualifying priority review voucher awarded on or before December 31, 2036, subject to a Board extension and a $50 million aggregate cap. The CVRs expire if no qualifying voucher is awarded by that date, unless extended. No Atossa product candidate has been approved by the FDA, and no voucher has been awarded.
CVRs transfer only with attached shares unless the Board elects to detach them. If Atossa uses a qualifying voucher or has an unsold voucher when a change of control occurs, the agreement treats that as a deemed monetization based on fair market value determined by an independent financial advisor. Atossa is not required to pursue development, approval or voucher monetization. Payments may be deferred under solvency and distribution limits and the obligation ends if a payment remains unpaid 24 months after its original due date.
Atossa Therapeutics, Inc. (ATOS) said its board approved a plan to issue one contingent value right (CVR) per common share. Under the proposed terms, holders would receive, in the aggregate, 25% of net proceeds from a qualifying event involving Atossa’s first qualifying rare pediatric disease priority review voucher, subject to a $50 million aggregate payment cap. A qualifying event could include Atossa using the voucher or holding it at the time of a change of control.
CVRs would attach to shares held by shareholders of record at the close of business on a record date to be established by the board, and to shares issued after that date. They would transfer with their ATOS shares unless detached by the board, and would not trade separately. Atossa has received two FDA rare pediatric disease designations for (Z)-endoxifen, but no product candidate has been approved and no voucher has been awarded to date; no CVR payment is assured. CVRs would expire if no qualifying voucher is awarded by December 31, 2036, unless the board extends that date.
Atossa Therapeutics, Inc. (ATOS) furnished an updated corporate and investor presentation outlining its (Z)-Endoxifen pipeline across breast cancer and rare diseases. The company reported $26 in cash and equivalents and no debt as of June 30, 2026, plus a June registered direct offering that raised $4 (net). The presentation highlights FDA Rare Pediatric Disease designation for McCune-Albright Syndrome (MAS) and Duchenne Muscular Dystrophy (DMD), and Orphan Drug Designation for DMD, which may confer Priority Review Voucher eligibility upon approval of a qualifying application. Clinical development milestones include completed Phase 2 enrollment in the EVANGELINE neoadjuvant breast cancer trial, anticipated top-line data in the fourth quarter of 2026, expected IND clearance for MAS and DMD in the second half of 2026, and planned Phase 2 trial initiations in 2027.
Atossa Therapeutics, a clinical-stage biopharmaceutical company focused on its lead candidate (Z)-endoxifen, reported financial results and a corporate update for the second quarter ended June 30, 2026. Total operating expenses were $8.7 million for the quarter and $18.6 million for the first half of 2026.
In Q2 2026, research and development expense was $4.9 million and general and administrative expense was $3.8 million. Net loss was $8,491 thousand for the quarter and $18,080 thousand year-to-date, with a basic and diluted net loss per share of $0.95 and $2.06, respectively. Cash and cash equivalents were $26,094 thousand at June 30, 2026.
Atossa highlighted new preclinical and clinical data supporting (Z)-endoxifen in McCune‑Albright Syndrome, Duchenne Muscular Dystrophy, and ER+ breast cancer, and completed enrollment in the EVANGELINE Phase 2 neoadjuvant breast cancer trial. A registered direct offering raised $4.5 million upfront and could provide up to an additional $12 million in gross proceeds to support (Z)-endoxifen development and general working capital.
Atossa Therapeutics, Inc. reported a net loss of $8.5 million for the quarter ended June 30, 2026, or $0.95 per share, as it continues clinical development of its lead drug candidate (Z)-endoxifen. For the first six months of 2026, net loss was $18.1 million, up from $15.1 million a year earlier, mainly due to higher general and administrative expenses tied to legal and intellectual-property matters, while research and development spending was roughly flat.
Cash and cash equivalents were $26.1 million as of June 30, 2026, down from $41.3 million at year-end after $19.2 million of operating cash outflows over six months. Management states these conditions raise substantial doubt about the company’s ability to continue as a going concern and expects existing resources will likely be insufficient to fund planned operations for the next twelve months without additional capital. In June 2026 Atossa completed a registered direct offering of 1,363,637 common shares with accompanying warrants, generating $4.0 million of net proceeds, and also began using a $50.0 million at-the-market facility. The company remains a pre-revenue, clinical-stage business advancing multiple Phase 2 (Z)-endoxifen trials and pursuing regulatory designations in oncology and rare diseases.
Atossa Therapeutics, Inc. is conducting a registered direct primary offering of 1,363,637 shares of common stock, each sold together with one Series A warrant and one Series B warrant, and placement agent warrants. The offering price is $3.30 per share with aggregate gross proceeds of $4,500,002.10. Net proceeds to the company before expenses are presented as $4,185,001.95 and the company estimates net proceeds after fees and expenses of approximately $4.1 million, to be used for clinical development, working capital and general corporate purposes. The warrants (totaling up to 2,727,274 shares) will be exercisable beginning six months after issuance at an exercise price of $4.40 per share; Series A warrants expire in five and one-half years and Series B warrants expire in two years. The placement agent will receive a cash fee equal to 7.0% of gross proceeds and placement agent warrants equal to 3.0% of shares sold to investors. Shares outstanding after the offering are stated as 9,974,997 (excluding shares issuable upon exercise of warrants and placement agent warrants) based on 8,611,361 shares outstanding as of March 31, 2026.
Atossa Therapeutics entered into a securities purchase agreement for a registered direct offering of 1,363,638 shares of common stock together with Series A and short-term Series B warrants, at a combined price of $3.30 per share and accompanying warrants. The Series A and Series B warrants each cover up to 1,363,638 shares at an exercise price of $4.40 per share, with exercises beginning six months after issuance; the Series A warrants expire 5.5 years after issuance and the Series B warrants expire two years after issuance. Atossa expects net proceeds of approximately $4.1 million from the share and warrant sale and may receive up to about $12 million in additional gross proceeds if all Series Warrants are exercised for cash. The company plans to use the net proceeds for clinical development of its product candidates, working capital and general corporate purposes.
Steinhart Richard I reported acquisition or exercise transactions in this Form 4 filing.
Atossa Therapeutics director Richard I. Steinhart received an equity award. He was granted 10,000 shares of common stock in the form of restricted stock units, with no cash price per share reported. Following this grant, he holds 10,000 shares directly.
The footnote explains that each RSU represents a contingent right to receive one share of common stock, and the RSUs will vest on the first anniversary of May 12, 2026. This is a compensation-related award, not an open‑market stock purchase or sale.
Chen Shu-Chih reported acquisition or exercise transactions in this Form 4 filing.
ATOSSA THERAPEUTICS, INC. director Shu-Chih Chen reported an equity award and updated holdings. Chen received a grant of 10,000 restricted stock units (RSUs), each representing the right to receive one share of common stock, at a price of $0.0000 per share. The RSUs vest on the first anniversary of May 12, 2026. Following this grant, Chen holds 10,000 common shares directly and 1,483 common shares indirectly through Ensisheim Partners, LLC, where voting and investment power is shared with Dr. Steven C. Quay, and beneficial ownership is disclaimed except to the extent of Chen’s pecuniary interest.
Remmel H. Lawrence reported acquisition or exercise transactions in this Form 4 filing.
ATOSSA THERAPEUTICS, INC. director Remmel H. Lawrence reported a compensation-related stock grant. He received 10,000 restricted stock units, each representing one share of common stock at no cash cost. These RSUs vest on the first anniversary of May 12, 2026. After this award, Lawrence directly holds 10,683 shares of common stock, reflecting a relatively small, routine equity grant rather than an open-market purchase.